NCT03551522 - A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

181

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

May 8, 2019

Study Completion Date

August 10, 2020

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

Seladelpar

10 mg, 20 mg, or 50 mg

DRUG

Placebos

Matching placebo Capsule

Trial Locations (14)

CymaBay Research Site, Boca Raton

CymaBay Research Site, Lakewood Rch

CymaBay Research Site, Clarksville

CymaBay Research Site, Hermitage

CymaBay Research Site, Knoxville

CymaBay Research Site, Germantown

CymaBay Research Site, Flowood

CymaBay Research Site, Dallas

CymaBay Research Site, Live Oak

CymaBay Research Site, Rollingwood

CymaBay Research Site, Chandler

CymaBay Research Site, Glendale

CymaBay Research Site, Tucson

CymaBay Research Site, Los Angeles